New Market Report: Lixte Biotechnology Holdings, Inc. - Product Pipeline Review - 2012

New Pharmaceuticals market report from Global Markets Direct: "Lixte Biotechnology Holdings, Inc. - Product Pipeline Review - 2012"

Logo

Boston, MA -- (SBWire) -- 10/20/2012 --Global Market Direct's pharmaceuticals report, "Lixte Biotechnology Holdings, Inc. - Product Pipeline Review - 2012" provides data on the Lixte Biotechnology Holdings, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Lixte Biotechnology Holdings, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Lixte Biotechnology Holdings, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Lixte Biotechnology Holdings, Inc. - Brief Lixte Biotechnology Holdings, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Lixte Biotechnology Holdings, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Lixte Biotechnology Holdings, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Lixte Biotechnology Holdings, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

View Full Report Details and Table of Contents

Reasons to Get this Report

- Evaluate Lixte Biotechnology Holdings, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Lixte Biotechnology Holdings, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Lixte Biotechnology Holdings, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Lixte Biotechnology Holdings, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Lixte Biotechnology Holdings, Inc. and identify potential opportunities in those areas.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Astrocytoma - Pipeline Review, H2 2012
- Circassia Holdings Ltd. - Product Pipeline Review - 2012
- Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2012
- Astrocytoma - Pipeline Review, H1 2012
- Alzheimer's Disease - Pipeline Review, H1 2012
- Melanoma - Pipeline Review, H2 2012
- Prana Biotechnology Limited - Product Pipeline Review - 2012
- Samyang Holdings Corporation - Product Pipeline Review - 2012
- Plethora Solutions Holdings plc - Product Pipeline Review - 2012
- Cytos Biotechnology AG - Product Pipeline Review - 2012

Media Relations Contact

Bill Thompson
Director of Marketing
800-844-8156
http://www.fastmr.com

View this press release online at: http://rwire.com/172755